Picture of Telcon RF Pharmaceutical logo

200230 Telcon RF Pharmaceutical Income Statement

0.000.00%
kr flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro CapValue Trap

Annual income statement for Telcon RF Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsARSAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue37,84127,83036,30737,86543,162
Cost of Revenue
Gross Profit9,1255,6649,58710,30910,205
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses43,49449,29836,66641,15438,283
Operating Profit-5,653-21,468-359-3,2884,878
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-22,875-42,11713,949-26,500-11,431
Provision for Income Taxes
Net Income After Taxes-22,875-42,11713,949-26,500-11,431
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-23,098-42,08413,906-26,320-11,456
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income-23,098-42,08415,330-26,320-11,456
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-610-628300-527-326
Dividends per Share